Numinus Wellness Inc. Selected for Cybin’s Phase 3 Trial on Depression Treatment

NEW YORK-  Numinus Wellness Inc.  announced that its research site, Cedar Clinical Research (CCR), has been chosen for Cybin’s Phase 3 clinical trial of CYB003, aimed at treating Major Depressive Disorder (MDD). This selection highlights a significant step in transforming mental health care.

The inclusion of CCR, located in Murray, Utah, among 15 U.S. sites for this trial underscores Numinus’s commitment to advancing innovative behavioral health treatments. This collaboration aims to explore new therapies that could significantly impact patient care.

Cybin’s Phase 2 trial results were promising, with 75% of participants achieving remission from depression symptoms four months after dosing with CYB003. These results led the U.S. Food and Drug Administration (FDA) to grant CYB003 breakthrough therapy designation.

The Phase 3 trial, starting enrollment in mid-2024, will investigate the safety and efficacy of CYB003. Dr. Paul Thielking, Numinus’s Chief Science Officer and Principal Investigator, expressed optimism about the trial, highlighting the impressive Phase 2 results and the potential to address a significant unmet need in mental health care.

Numinus Founder and CEO Payton Nyquvest emphasized the importance of this partnership in advancing psychedelic-assisted therapy, viewing 2024 as a pivotal year for this field.

This collaboration represents a significant milestone in clinical research, offering hope to millions affected by MDD. The commitment of Numinus and Cybin to innovative and evidence-based treatments aims to not only manage but potentially heal depression.

As the trial progresses, both companies plan to share their findings transparently, aiming to advance CYB003 as a potential adjunctive psychedelic-based therapeutic for MDD. This trial signifies a hopeful development for those affected by MDD, indicating a future where innovative treatments could provide substantial relief and healing.